EpiVax Revenue and Competitors
Estimated Revenue & Valuation
- EpiVax's estimated annual revenue is currently $8.4M per year.
- EpiVax's estimated revenue per employee is $155,000
Employee Data
- EpiVax has 54 Employees.
- EpiVax grew their employee count by 6% last year.
EpiVax's People
| Name | Title | Email/Phone |
|---|---|---|
1 | FOUNDER, CEO & CSO | Reveal Email/Phone |
2 | Senior Director Immunology and Protein Therapeutics | Reveal Email/Phone |
3 | Director Bioinformatics | Reveal Email/Phone |
4 | Director Human Resources | Reveal Email/Phone |
5 | Scientific Director, PreClinical Immunology | Reveal Email/Phone |
6 | Director IT | Reveal Email/Phone |
7 | Office Manager | Reveal Email/Phone |
8 | Bioinformatics, Senior Project Manager | Reveal Email/Phone |
9 | Program Manager, Preclinical Immunology | Reveal Email/Phone |
10 | Laboratory Manager | Reveal Email/Phone |
EpiVax Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1M | 13 | -19% | N/A | N/A |
#2 | $0.8M | 5 | -29% | N/A | N/A |
#3 | $0.9M | 6 | 20% | N/A | N/A |
#4 | $0.8M | 5 | 0% | N/A | N/A |
#5 | $0.9M | 6 | -14% | N/A | N/A |
#6 | $0.7M | 9 | 0% | N/A | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $1.9M | 12 | 0% | N/A | N/A |
#9 | $14.9M | 96 | 57% | N/A | N/A |
#10 | $1.4M | 9 | 0% | N/A | N/A |
What Is EpiVax?
EpiVax is Hiring! Please see our Careers Page - http://epivax.com/about-us/careers EpiVax uses immune-engineering to develop new vaccines and to improve the immunogenicity profiles of new drugs. The company is well known for its independent thinking and interdisciplinary scientists. Thinking outside the box at EpiVax has often led to paradigm-shifting discoveries. Responsibility is another key attribute: EpiVax counts 6 of the eight largest Biotech companies in the world among its clients. EpiVax is also globally responsible: the company supports a number of not-for-profits that improve human health around the world. The company was founded in 1998 with support from the Slater Biotechnology Fund. In 2002, EpiVax was invited by the FDA to participate in one of the first ever "Immunogenicity" meetings. By 2006, EpiVax had developed a reputation as “thought leaders†in the field of therapeutic proteins and immunogenicity screening, providing fee-for-service solutions for first tier Pharma companies, mid to small biotech companies, and academics. The company has a solid reputation for publishing its work in academic journals (>170 publications, compared to
keywords:N/A
N/A
Total Funding
54
Number of Employees
$8.4M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
EpiVax News
EpiVax; Novozymes Biopharma; ioGenetics; International Society of Vaccines; IMGT; Dassault Systemes; Certara; Chemical Computing Group; Compugen...
... Vaccine Market 2022 Technology Landscape and Opportunities Report 2028 | Key Players as Bavarian Nordic, CEL-SCI, Chimerix, EpiVax.
Other Companies in Providence
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.5M | 54 | 8% | N/A |
#2 | $7.5M | 54 | 8% | N/A |
#3 | $7.5M | 54 | 4% | N/A |
#4 | $10.6M | 56 | 4% | N/A |
#5 | $15M | 57 | -5% | N/A |